Altimmune Inc (NAS:ALT)

$ 7.33 -0.06 (-0.81%) Market Cap: 519.71 Mil Enterprise Value: 338.24 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 30/100

Q4 2023 Altimmune Inc Earnings Call Transcript
Mar 27, 2024

$8.89 (+2.77%)

Earnings
Altimmune Inc Conference Call Transcript
Dec 01, 2023
Q3 2023 Altimmune Inc Earnings Call Transcript
Nov 07, 2023

$2.7 (+1.12%)

Earnings
Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Oct 25, 2023
Altimmune Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Altimmune Inc Earnings Call Transcript
Aug 10, 2023

$3.04 (+3.05%)

Earnings
Altimmune Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Altimmune Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Altimmune Inc Earnings Call Transcript
May 11, 2023

$5.33 (+7.03%)

Earnings
Altimmune Inc Conference Call Transcript
Mar 21, 2023
Q4 2022 Altimmune Inc Earnings Call Transcript
Feb 28, 2023

$12.59 (+6.42%)

Earnings
Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call Transcript
Dec 20, 2022
Altimmune Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Q3 2022 Altimmune Inc Earnings Call Transcript
Nov 10, 2022

$10.58 (+9.18%)

Earnings
Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference Transcript
Oct 18, 2022
Altimmune Inc Conference Call Transcript
Sep 14, 2022
Q2 2022 Altimmune Inc Earnings Call Transcript
Aug 11, 2022

$13.77 (+7.08%)

Earnings
Altimmune Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 Altimmune Inc Earnings Call Transcript
May 12, 2022

$4.28 (+8.63%)

Earnings
Q4 2021 Altimmune Inc Earnings Call Transcript
Mar 15, 2022

$5.9 (-8.24%)

Earnings
Q3 2021 Altimmune Inc Earnings Call Transcript
Nov 10, 2021

$10.92

Earnings
Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call Transcript
Sep 30, 2021
Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call Transcript
Sep 28, 2021
Q2 2021 Altimmune Inc Earnings Call Transcript
Aug 11, 2021

$11.15 (+2.48%)

Earnings
Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call Transcript
Jun 16, 2021
Q1 2021 Altimmune Inc Earnings Call Transcript
May 17, 2021

$14.18 (+5.98%)

Earnings
Altimmune Inc to Present AdCOVID™ intranasal COVID-19 at the World Vaccine Congress Transcript
May 04, 2021
Q4 2020 Altimmune Inc Earnings Call Transcript
Feb 25, 2021

$17.2 (-12.16%)

Earnings
Q3 2020 Altimmune Inc Earnings Call Transcript
Nov 10, 2020

$9.33 (+19.08%)

Earnings
Altimmune Inc Annual Shareholders Meeting Transcript
Sep 24, 2020
Q2 2020 Altimmune Inc Earnings Call Transcript
Aug 12, 2020

$22.58 (-2.25%)

Earnings
Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call Transcript
Jun 01, 2020
Q1 2020 Altimmune Inc Earnings Call Transcript
May 14, 2020

$4.49 (+8.72%)

Earnings
Q4 2019 Altimmune Inc Earnings Call Transcript
Mar 27, 2020

$2.85 (-12.31%)

Earnings
Q2 2019 Altimmune Inc Earnings Call Transcript
Aug 14, 2019

$2.03 (-4.25%)

Earnings

Altimmune Inc Conference Call Transcript

Mar 21, 2023 / 12:30PM GMT

Release Date Price: $4.95 (-54.67%)

Transcript

Operator

Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. MOMENTUM Pemvidutide Phase II Obesity Trial Week 24 Interim Analysis Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin.

Richard I. Eisenstadt

Altimmune, Inc. - CFO

Thank you, operator, and good morning, everyone. Thank you for participating in the conference call to discuss the results of the week 24 interim analysis of the MOMENTUM pemvidutide Phase II obesity trial. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer; Scott Harris (sic) [Scot Roberts], our Chief Scientific Officer; Scott Harris, our Chief Medical Officer; and Dr. Louis Aronne, Professor of Metabolic Research and Professor of Clinical Medicine, Weill Cornell Medicine, the principal investigator of the MOMENTUM obesity trial.

On today's call, we will also discuss the results of our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.